Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes

D. Dowlatshahi; A. M. Demchuk; M. L. Flaherty; Myzoon Ali; P. L. Lyden; E.E. Smith

doi:10.1212/WNL.0b013e3182143317

Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes

D. Dowlatshahi, A. M. Demchuk, M. L. Flaherty, Myzoon Ali, P. L. Lyden, E.E. Smith

Research output: Contribution to journal › Article › peer-review

Abstract

Hematoma expansion (HE) is a surrogate marker in intracerebral hemorrhage (ICH) trials. However, the amount of HE necessary to produce poor outcomes in an individual is unclear; there is no agreement on a clinically meaningful definition of HE. We compared commonly used definitions of HE in their ability to predict poor outcome as defined by various cutpoints on the modified Rankin Scale (mRS). In this cohort study, we analyzed 531 patients with ICH from the Virtual International Stroke Trials Archive. Primary outcome was mRS at 90 days, dichotomized into 0–3 vs 4–6. Secondary outcomes included other mRS cutpoints and mRS “shift analysis.” Sensitivity, specificity, and predictive values for commonly used HE definitions were calculated.

Original language	English
Pages (from-to)	1238-1244
Number of pages	7
Journal	Neurology
Volume	76
Issue number	14
DOIs	https://doi.org/10.1212/WNL.0b013e3182143317
Publication status	Published - 1 Apr 2011

Keywords

hematoma
stroke
intracerebral hemorrhage

Documents and Links

10.1212/WNL.0b013e3182143317

Fingerprint Dive into the research topics of 'Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes'. Together they form a unique fingerprint.

Cite this

@article{0e4e36c8aeeb49fcb9cbbc4dcc7944f8,

title = "Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes",

abstract = "Hematoma expansion (HE) is a surrogate marker in intracerebral hemorrhage (ICH) trials. However, the amount of HE necessary to produce poor outcomes in an individual is unclear; there is no agreement on a clinically meaningful definition of HE. We compared commonly used definitions of HE in their ability to predict poor outcome as defined by various cutpoints on the modified Rankin Scale (mRS). In this cohort study, we analyzed 531 patients with ICH from the Virtual International Stroke Trials Archive. Primary outcome was mRS at 90 days, dichotomized into 0–3 vs 4–6. Secondary outcomes included other mRS cutpoints and mRS “shift analysis.” Sensitivity, specificity, and predictive values for commonly used HE definitions were calculated.",

keywords = "hematoma, stroke, intracerebral hemorrhage",

author = "D. Dowlatshahi and Demchuk, {A. M.} and Flaherty, {M. L.} and Myzoon Ali and Lyden, {P. L.} and E.E. Smith",

note = "<p>Originally published in: Neurology (2011), 76 (14), pp.1238-1244.</p>",

year = "2011",

month = apr,

day = "1",

doi = "10.1212/WNL.0b013e3182143317",

language = "English",

volume = "76",

pages = "1238--1244",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "14",

}

TY - JOUR

T1 - Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes

AU - Dowlatshahi, D.

AU - Demchuk, A. M.

AU - Flaherty, M. L.

AU - Ali, Myzoon

AU - Lyden, P. L.

AU - Smith, E.E.

N1 - <p>Originally published in: Neurology (2011), 76 (14), pp.1238-1244.</p>

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Hematoma expansion (HE) is a surrogate marker in intracerebral hemorrhage (ICH) trials. However, the amount of HE necessary to produce poor outcomes in an individual is unclear; there is no agreement on a clinically meaningful definition of HE. We compared commonly used definitions of HE in their ability to predict poor outcome as defined by various cutpoints on the modified Rankin Scale (mRS). In this cohort study, we analyzed 531 patients with ICH from the Virtual International Stroke Trials Archive. Primary outcome was mRS at 90 days, dichotomized into 0–3 vs 4–6. Secondary outcomes included other mRS cutpoints and mRS “shift analysis.” Sensitivity, specificity, and predictive values for commonly used HE definitions were calculated.

AB - Hematoma expansion (HE) is a surrogate marker in intracerebral hemorrhage (ICH) trials. However, the amount of HE necessary to produce poor outcomes in an individual is unclear; there is no agreement on a clinically meaningful definition of HE. We compared commonly used definitions of HE in their ability to predict poor outcome as defined by various cutpoints on the modified Rankin Scale (mRS). In this cohort study, we analyzed 531 patients with ICH from the Virtual International Stroke Trials Archive. Primary outcome was mRS at 90 days, dichotomized into 0–3 vs 4–6. Secondary outcomes included other mRS cutpoints and mRS “shift analysis.” Sensitivity, specificity, and predictive values for commonly used HE definitions were calculated.

KW - hematoma

KW - stroke

KW - intracerebral hemorrhage

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-79954586094&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3182143317

DO - 10.1212/WNL.0b013e3182143317

M3 - Article

VL - 76

SP - 1238

EP - 1244

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 14

ER -